Clinical trials: Hepatic Cell Carcinoma
Localized Non-Resectable Adult Hepatocellular Carcinoma
Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres
Chemoembolization is a recognized treatment strategy for hepatocellular carcinoma (HCC) classical chemoembolization consists in injecting an emulsion of an anticancer agent in Lipiodol® via the hepatic artery doxorubicin, an…
- Trial name
- IDASPHERE (NCT02870010)
- Testing
- blood samples (5 ml) will be taken, Chemoembolization
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hepatocellular Carcinoma
Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC
Short-term outcomes of laparoscopic liver resection is better than those of open liver resection Laparoscopic liver resection is better than open resection in immunological aspects
- Trial name
- HCC (NCT00606385)
- Testing
- Liver resection
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Seoul National University Hospital
Liver Carcinoma Resectable
Trans-parenchymal Compressing Suture in Major Liver Resection
Non-anatomical liver resection with appropriate resection margin was regarded as a potential curative treatment for selected major hepatic carcinoma due to preserving maximal normal liver, especially in cirrhotic patients.
- Trial name
- NCT03215290
- Testing
- TCS
- Volunteers
- 382 people
- Sponsor
- Tongji Hospital
Liver Cancer
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
- Trial name
- NCT05717400
- Testing
- Bevacizumab, Atezolizumab, Sofosbuvir
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01266707
- Testing
- antiangiogenic paptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Fukushima Medical University
Hepatocellular Carcinoma (HCC)
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
The objective of this retrospective cohort study is to investigate the therapeutic effects of combined immunotherapy and targeted therapy, with or without radiotherapy, in patients with hepatocellular carcinoma.
- Trial name
- RIO-HCC (NCT06639971)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
- Trial name
- NCT05223816
- Testing
- VG161, Nivolumab Injection [Opdivo]
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Virogin Biotech Canada Ltd
Hepatocellular Carcinoma
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
- Trial name
- NCT05320692
- Testing
- TACE+Camrelizumab+Apatinib mesylate, TACE
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included patients will randomly divide into two groups.
- Trial name
- NCT02650271
- Testing
- Entecavir, Tenofovir
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited.
- Trial name
- NCT05620706
- Testing
- GPC3 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Hepatocellulcar Carcinoma
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment…
- Trial name
- NCT07238881
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
This open-label, multicenter phase II study was designed to evaluate the safety and efficacy of JS207 alone or in combination with JS007 as first-line treatment in subjects with advanced HCC.
- Trial name
- NCT06954467
- Testing
- JS207, JS007
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
This phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating patients with liver cancer that cannot…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04605731
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
HCC
Phase IB/II Study of NRT Combined With Radiotherapy for Advanced HCC
The study herein successfully developed a new immunotherapeutic approach combined with radiotherapy, and tried to proved it to be more effective and safe.
- Trial name
- LCRAI-1 (NCT03199807)
- Testing
- NRT, Radiotherapy
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Carcinoma, Hepatocellular
Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
Hepatocellular carcinoma (HCC) is a deadly tumor for which the incidence is increasing in the United States, primarily due to prevalence of hepatitis C infection.
- Trial name
- NCT00006332
- Testing
- Tetrathiomolybdate
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Liver Neoplasms
Liver Cancer Prognosis Investigation Study
This prospective cohort study is designed to explore the role of environmental, clinical, and genetic risk factors in the progression and prognosis of primary liver cancer (PLC).
- Trial name
- NCT06623734
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University